Our Platform

A FOCUS ON KINASE THERAPEUTICS 

We focus on creating a new class of drugs targeted against the human kinome, a family of 500 proteins associated with diseases such as cancer, auto-immunity and neurodegeneration 

KINASE SYNERGIES

We integrate genetic screening, literature mining, multi-omics and drug combination data to predict synergistic protein targets as well as avoid specific toxic anti-targets for a given indication

CHEMICAL STRUCTURE DESIGN

Given a set of kinase targets and anti-targets, we use machine learning, chemical informatics and medicinal chemistry to rationally design a molecule with the desired binding profile

KINOME BINDING PREDICTOR

After designing our molecules, we predict all off-target interactions across the whole kinome 

MULTI-TARGET HIT SERIES AND LEAD OPTMIZATION

Our initial hit-series are then optimized to improve selectivity of our multi-target inhibitors